Related Experiment Video

Updated: Jul 6, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Renal cell carcinoma and the use of sorafenib

James Mg Larkin1, Tim Eisen

  • 1Department of Medicine, Royal Marsden Hospital, Downs Road Sutton, Surrey SM2 5PT, UK.

Therapeutics and Clinical Risk Management
|March 25, 2008
PubMed

Insights

New kinase inhibitor sorafenib shows promise for metastatic renal cell carcinoma (RCC). This targeted therapy offers improved progression-free survival and manageable toxicity, addressing the need for better systemic treatments in advanced kidney cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) has limited treatment options, with immunotherapy offering only a small survival benefit.
  • Angiogenesis, driven by vascular endothelial growth factor (VEGF), is crucial in RCC development.
  • There is a significant need for more effective systemic therapies for advanced RCC.

Purpose of the Study:

  • To evaluate the efficacy and safety of sorafenib, a novel kinase inhibitor, in patients with metastatic renal cell carcinoma (RCC).
  • To assess sorafenib's role in targeting key pathways involved in RCC pathophysiology, including VEGF and platelet-derived growth factor (PDGF).

Main Methods:

  • Phase 2 studies assessed sorafenib activity and toxicity in patients pretreated with immunotherapy.
  • Phase 3 studies compared sorafenib to placebo, evaluating progression-free survival.
  • Ongoing and planned phase 3 trials investigate sorafenib in advanced disease and as adjuvant therapy.

Main Results:

  • Sorafenib demonstrated significant activity with manageable toxicity in phase 2 metastatic RCC studies.
  • Phase 3 studies reported prolonged progression-free survival for sorafenib compared to placebo.
  • Further clinical trials are underway to confirm these findings and explore broader applications.

Conclusions:

  • Sorafenib represents a promising targeted therapy for metastatic renal cell carcinoma (RCC).
  • Its ability to inhibit key angiogenic pathways offers a new strategy for managing advanced kidney cancer.
  • Ongoing research will further define sorafenib's role in RCC treatment paradigms.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...